Genetic aberrations and survival in plasma cell leukemia von Tiedemann, R E, Gonzalez-Paz, N, Kyle, R A, Santana-Davila, R, Price-Troska, T, Van Wier, S A, Chng, W J, Ketterling, R P, Gertz, M A, Henderson, K, Greipp, P R, Dispenzieri, A, Lacy, M Q, Rajkumar, S V, Bergsagel, P L, Stewart, A K, Fonseca, R

Volltext

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) von Lacy, M Q, Hayman, S R, Gertz, M A, Short, K D, Dispenzieri, A, Kumar, S, Greipp, P R, Lust, J A, Russell, S J, Dingli, D, Zeldenrust, S, Fonseca, R, Bergsagel, P L, Roy, V, Mikhael, J R, Stewart, A K, Laumann, K, Allred, J B, Mandrekar, S J, Rajkumar, S V, Buadi, F

Volltext

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study von Vesole, D H, Oken, M M, Heckler, C, Greipp, P R, Katz, M S, Jacobus, S, Morrow, G R

Volltext

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system von Snozek, C L H, Katzmann, J A, Kyle, R A, Dispenzieri, A, Larson, D R, Therneau, T M, Melton, L J, Kumar, S, Greipp, P R, Clark, R J, Rajkumar, S V

Volltext

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells von KLINE, M. P, RAJKUMAR, S. V, TIMM, M. M, KIMLINGER, T. K, HAUG, J. L, LUST, J. A, GREIPP, P. R, KUMAR, S

Volltext

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy von STEWART, A. K, BERGSAGEL, P. L, WITZIG, T. E, ZELDENRUST, S. R, DINGLI, D, REEDER, C. B, ROY, V, KYLE, R. A, RAJKUMAR, S. V, FONSECA, R, GREIPP, P. R, DISPENZIERI, A, GERTZ, M. A, HAYMAN, S. R, KUMAR, S, LACY, M. Q, LUST, J. A, RUSSELL, S. J

Volltext

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma von FONSECA, R, VAN WIER, S. A, PRICE-TROSKA, T, HENDERSON, K. J, AHMANN, G. J, GERTZ, M. A, CHNG, W. J, KETTERLING, R, LACY, M. Q, DISPENZIERI, A, BERGSAGEL, P. L, RAJKUMAR, S. V, GREIPP, P. R, LITZOW, M. R

Volltext

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and or transplant ineligible patients with multiple myeloma: a meta-analysis von Kapoor, P, Rajkumar, S V, Dispenzieri, A, Gertz, M A, Lacy, M Q, Dingli, D, Mikhael, J R, Roy, V, Kyle, R A, Greipp, P R, Kumar, S, Mandrekar, S J

Volltext

Thalidomide as initial therapy for early-stage myeloma von RAJKUMAR, S. V, GERTZ, M. A, GREIPP, P. R, WITZIG, T. E, LACY, M. Q, DISPENZIERI, A, FONSECA, R, GEYER, S. M, ITURRIA, N, KUMAR, S, LUST, J. A, KYLE, R. A

Volltext

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations von CHNG, W. J, SANTANA-DAVILA, R, OKEN, M. M, HENDERSON, K, KYLE, R. A, GERTZ, M. A, LACY, M. Q, DISPENZIERI, A, GREIPP, P. R, FONSECA, R, VAN WIER, S. A, AHMANN, G. J, JALAL, S. M, BERGSAGEL, P. L, CHESI, M, TRENDLE, M. C, JACOBUS, S, BLOOD, E

Volltext

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma von Witzig, T E, Laumann, K M, Lacy, M Q, Hayman, S R, Dispenzieri, A, Kumar, S, Reeder, C B, Roy, V, Lust, J A, Gertz, M A, Greipp, P R, Hassoun, H, Mandrekar, S J, Rajkumar, S V

Volltext

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma von DEBES-MARUN, C. S, DEWALD, G. W, DISPENZIERI, A, LACY, M. Q, RAJKUMAR, S. V, LUST, J. A, GREIPP, P. R, FONSECA, R, BRYANT, S, PICKEN, E, SANTANA-DAVILA, R, GONZALEZ-PAZ, N, WINKLER, J. M, KYLE, R. A, GERTZ, M. A, WITZIG, T. E

Volltext

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial von Dispenzieri, A, Jacobus, S, Vesole, D H, Callandar, N, Fonseca, R, Greipp, P R

Volltext

Expression of VEGF and its receptors by myeloma cells von KUMAR, S, WITZIG, T. E, TIMM, M, HAUG, J, WELLIK, L, FONSECA, R, GREIPP, P. R, RAJKUMAR, S. V

Volltext

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma von KUMAR, S, WITZIG, T. E, RAJKUMAR, S. V, DISPENZIERI, A, LACY, M. Q, WELLIK, L. E, FONSECA, R, LUST, J. A, GERTZ, M. A, KYLE, R. A, GREIPP, P. R

Volltext

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy von KUMAR, S, LACY, M. Q, KYLE, R. A, LITZOW, M. R, GERTZ, M. A, DISPENZIERI, A, RAJKUMAR, S. V, FONSECA, R, GEYER, S, ALLMER, C, WITZIG, T. E, LUST, J. A, GREIPP, P. R

Volltext

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations von KUMAR, S, RAJKUMAR, S. V, KIMLINGER, T, GREIPP, P. R, WITZIG, T. E

Volltext

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma von Kumar, S, Zhang, L, Dispenzieri, A, Van Wier, S, Katzmann, J A, Snyder, M, Blood, E, DeGoey, R, Henderson, K, Kyle, R A, Bradwell, A R, Greipp, P R, Rajkumar, S V, Fonseca, R

Volltext

Thalidomide for previously untreated indolent or smoldering multiple myeloma von RAJKUMAR, S. V, DISPENZIERI, A, FONSECA, R, LACY, M. Q, GEYER, S, LUST, J. A, KYLE, R. A, GREIPP, P. R, GERTZ, M. A, WITZIG, T. E

Volltext

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis von Ocio, E. M., Schop, R. F. J., Gonzalez, B., Van Wier, S. A., Hernandez‐Rivas, J. M., Gutierrez, N. C., Garcia‐Sanz, R., Moro, M. J., Aguilera, C., Hernandez, J., Xu, R., Greipp, P. R., Dispenzieri, A., Jalal, S. M., Lacy, M. Q., Gonzalez‐Paz, N., Gertz, M. A., San Miguel, J. F., Fonseca, R.

Volltext